BOSTON & NEW YORK--(BUSINESS WIRE)--Anji Pharmaceuticals and Population Health Partners today announced that they have entered into a strategic collaboration, bringing together two complementary teams to jointly address high prevalence human diseases.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anji Pharma, an emerging global medicines company, today announced successful completion of a pharmacokinetic (PK) study of ANJ900 in healthy Chinese volunteers to enable initiation of a pivotal clinical program in China later this year. ANJ900, a delayed-release formulation of metformin, is currently being studied in an ongoing multinational Phase 3 trial, DREAM-T2D, in type 2 diabetes (T2D) patients with normal, mild, and moderate chronic kidney disease (CKD stages 1-3B).
CAMBRIDGE, Mass. & SHANGHAI--(BUSINESS WIRE)--Anji Pharma, an emerging global medicines company, today announced it has completed enrollment in its Phase 2 proof of concept study of pradigastat (ANJ908), a diacylglycerol acyltransferase 1 (DGAT1) inhibitor, in patients with functional constipation. The trial is being conducted in five clinical sites in the U.S. and 20 clinical sites in China. Anji plans to report topline data from this study in the second half of 2022.
Eli Lilly is among the investors backing preclinical biotech IpiNovyx Bio as it emerges with $10 million to go after inflammatory and autoimmune diseases.
Anji Pharma wants to bring a Type 2 diabetes and chronic kidney disease treatment along with a constipation drug to market, and now the biotech has $70 million to bankroll clinical trials.